The Window of Vulnerability

There are three points in a woman's life when the risk of depression rises measurably: puberty, the period after childbirth, and the menopause transition. All three involve significant hormonal reorganisation. The first two are widely recognised. The third is not.

That gap has consequences. Women arrive at 47 with symptoms that would be immediately recognised at 27 with a newborn, and get told they're stressed.

What the research found

Two large longitudinal studies, tracking women through the transition rather than asking them to recall it afterwards, produced converging results.

The Penn Ovarian Aging Study followed women with no history of depression and found the risk of a first depressive episode substantially higher during perimenopause than during the premenopausal years — roughly a fourfold increase in the risk of developing depressive symptoms.

SWAN found a similar pattern, with women two to four times more likely to experience clinically significant depressive symptoms during perimenopause compared with premenopause.

Two features are worth noting. The elevated risk applies to women with no prior history — this isn't only a recurrence phenomenon. And the risk appears to fall again after the transition, which is where the "window" framing comes from.

Who's at higher risk

Not evenly distributed. The factors that recur across studies:

A previous episode of depression, at any point. A history of premenstrual mood symptoms, or of postnatal depression — both suggest heightened sensitivity to hormonal change rather than to hormone levels as such. A longer transition. Severe vasomotor symptoms, particularly with disrupted sleep. Significant life stressors, which the years between 45 and 55 supply generously.

If several of those describe you, it's worth knowing in advance rather than in retrospect.

Why it gets missed

It doesn't always look like sadness. Perimenopausal depression frequently presents as irritability, flatness, loss of interest, or a sense of everything being effortful, rather than as low mood. Women say "I don't feel sad, I just don't feel anything much" and it doesn't get coded as depression by anyone in the room.

The symptoms overlap. Fatigue, poor sleep, low concentration, appetite change and reduced libido are all on the depression criteria and all common in perimenopause without depression. Untangling them requires actually asking.

It's explained away by circumstance. There is always a plausible external reason at this age — the job, the teenagers, the parents, the marriage. All real. None of which means the low mood isn't also a treatable condition.

Women don't report it. The most common reason it's missed. It gets absorbed into the general expectation that this stage is hard.

Treatment, and the part that's genuinely unresolved

The honest position: the evidence on whether hormone therapy or antidepressants should come first is incomplete, and it depends on the specific picture.

Expert guidance from a task force convened jointly by menopause and women's mental health specialists concluded that antidepressants remain first-line for a diagnosed major depressive episode, and that estrogen therapy has evidence for depressive symptoms in perimenopausal — though not postmenopausal — women.

NICE takes a related position that's worth knowing because it protects you from a common error. It advises considering HRT for low mood arising as a result of menopause, and considering CBT for low mood or anxiety in this context. And it notes there is no clear evidence for SSRIs or SNRIs easing low mood in menopausal women who have not been diagnosed with depression.

That last point matters, because the most common frustration women report from these appointments is being offered an antidepressant for something that hadn't been assessed as depression.

The practical reading: if you have a diagnosable depressive episode, antidepressants are an evidence-based treatment and shouldn't be resisted out of principle. If you have low mood in a cluster of menopausal symptoms, HRT and CBT are legitimate things to discuss. Sometimes both are appropriate. What isn't appropriate is a reflex prescription without an actual assessment.

What to say

If you're going to raise this, structure helps. Describe how long it's been going on, whether it's present most days, what you've stopped doing that you used to do, and whether it correlates with your cycle or with sleep.

Then be explicit about what you want: "I'd like this assessed properly rather than assumed to be menopausal — and if it is menopausal, I'd like to discuss the options including HRT and CBT, not only antidepressants."

The line that isn't negotiable

If you have thoughts of ending your life, or of not wanting to be here, tell someone today. A doctor, a crisis line, a person in your house. Not next week.

That is not an overreaction and it is not a failure of resilience. It is the correct response to a symptom that is treatable and dangerous to sit with alone.

Sources

- Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Archives of General Psychiatry. 2006;63(4):375–382. - Bromberger JT, Kravitz HM, Chang YF, et al. Major depression during and after the menopausal transition: Study of Women's Health Across the Nation (SWAN). Psychological Medicine. 2011;41(9):1879–1888. - Maki PM, Kornstein SG, Joffe H, et al. Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. Menopause. 2018;25(10):1069–1085. - National Institute for Health and Care Excellence. Menopause: identification and management (NG23). Updated 2024.